Table II.
Summary of treatment outcomes in patients with primary and secondary PEO
| PEO treatment | Number of patients treated (n) | Complete resolution | Time to complete resolution (days) | Partial resolution | Time to partial resolution (days) | No resolution | Worsening | Mean follow-up period post treatment (months) |
|---|---|---|---|---|---|---|---|---|
| Monotherapy | ||||||||
| Corticosteroid (oral) | 29 | 9 (31.0%) | 24.0 (n = 2) | 16 (55.2%) | 38.0 (n = 3) | 3 (10.3%) | 1 (3.4%) | 70.7 (n = 14) |
| PUVA | 21 | 13 (61.9%) | 105.0 (n = 10) | 7 (33.3%) | 106.5 (n = 4) | 0 (0.0%) | 1 (4.8%) | 72.9 (n = 14) |
| Corticosteroid (topical) | 9 | 1 (11.1%) | 14.0 (n = 1) | 5 (55.6%) | NR | 3 (33.3%) | 0 (0.0%) | 3.0 (n = 1) |
| UVB | 8 | 3 (37.5%) | NR | 1 (12.5%) | NR | 4 (50.0%) | 0 (0.0%) | 108.0 (n = 1) |
| Retinoid (oral) | 8 | 7 (87.5%) | 25.0 (n = 7) | 1 (12.5%) | NR | 0 (0.0%) | 0 (0.0%) | 24.0 (n = 1) |
| Treating underlying condition | 7 | 2 (28.6%) | 2.0 (n = 1) | 5 (71.4%) | 14.0 (n = 1) | 0 (0.0%) | 0 (0.0%) | 13.0 (n = 2) |
| Immunosuppressant | 6 | 3 (50%) | 120.0 (n = 1) | 2 (33.3%) | NR | 1 (16.7%) | 0 (0.0%) | 10.5 (n = 2) |
| IL-4 inhibitor | 3 | 1 (33.3%) | 98.0 (n = 1) | 2 (66.7%) | 90.0 (n = 1) | 0 (0.0%) | 0 (0.0%) | 8.3 (n = 3) |
| Antihistamine | 2 | 0 (0.0%) | N/A | 0 (0.0%) | N/A | 1 (50.0%) | 1 (50.0%) | 108.0 (n = 1) |
| Antibiotic | 2 | 1 (50.0%) | 90.0 (n = 1) | 1 (50.0%) | NR | 0 (0.0%) | 0 (0.0%) | NR |
| Interferon-α | 1 | 1 (100.0%) | 28.0 (n = 1) | 0 (0.0%) | N/A | 0 (0.0%) | 0 (0.0%) | NR |
| Antifungal | 1 | 0 (0.0%) | N/A | 1 (100.0%) | NR | 0 (0.0%) | 0 (0.0%) | NR |
| Androgen deprivation | 1 | 0 (0.0%) | N/A | 1 (100.0%) | 28.0 (n = 1) | 0 (0.0%) | 0 (0.0%) | NR |
| No treatment | 1 | 1 (100.0%) | NR | 0 (0.0%) | N/A | 0 (0.0%) | 0 (0.0%) | NR |
| Combination therapy | ||||||||
| Corticosteroid (topical), antihistamine | 33 | 3 (9.1%) | 21.0 (n = 1) | 8 (24.2%) | 226.3 (n = 3) | 16 (48.5%) | 6 (18.2%) | 58.4 (n = 3) |
| Corticosteroid (topical), corticosteroid (oral) | 9 | 0 (0.0%) | N/A | 3 (33.3%) | NR | 6 (66.7%) | 0 (0.0%) | 16.8 (n = 6) |
| Corticosteroid (topical), PUVA | 9 | 4 (44.4%) | NR | 3 (33.3%) | 7.0 (n = 1) | 1 (11.1%) | 1 (11.1%) | 108.0 (n = 6) |
| Corticosteroid (topical), UVB | 7 | 2 (28.6%) | NR | 5 (71.4%) | NR | 0 (0.0%) | 0 (0.0%) | 87.6 (n = 5) |
| Corticosteroid (topical), corticosteroid (oral), antihistamine | 5 | 3 (60.0%) | 10.0 (n = 3) | 2 (40.0%) | NR | 0 (0.0%) | 0 (0.0%) | 20.0 (n = 3) |
| Corticosteroid (topical), antihistamine, immunosuppressant∗,† | 2 | 0 (0.0%) | N/A | 1 (50.0%) | NR | 1 (50.0%) | 0 (0.0%) | 7.0 (n = 1) |
| Corticosteroid (topical), antihistamine, PUVA | 2 | 0 (0.0%) | N/A | 0 (0.0%) | N/A | 1 (50.0%) | 1 (50.0%) | 8.0 (n = 2) |
| Corticosteroid (topical), corticosteroid (oral), antihistamine, antibiotic‡ | 2 | 0 (0.0%) | N/A | 1 (50.0%) | NR | 1 (50.0%) | 0 (0.0%) | 7.5 (n = 2) |
| Corticosteroid (topical), antibiotic§ | 1 | 0 (0.0%) | N/A | 1 (100.0%) | NR | 0 (0.0%) | 0 (0.0%) | 20.0 (n = 1) |
| Corticosteroid (topical), antihistamine, UVB | 1 | 0 (0.0%) | N/A | 0 (0.0%) | N/A | 1 (100.0%) | 0 (0.0%) | 12.0 (n = 1) |
| Corticosteroid (topical), corticosteroid (oral), immunosuppressant‖ | 1 | 0 (0.0%) | N/A | 0 (0.0%) | N/A | 1 (100.0%) | 0 (0.0%) | NR |
| Corticosteroid (topical), corticosteroid (oral), antihistamine, UVB | 1 | 0 (0.0%) | N/A | 1 (100.0%) | NR | 0 (0.0%) | 0 (0.0%) | 12.0 (n = 1) |
| Corticosteroid (topical), corticosteroid (oral), antihistamine, retinoid (oral), immunosuppressant∗ | 1 | 0 (0.0%) | N/A | 1 (100.0%) | NR | 0 (0.0%) | 0 (0.0%) | 12.0 (n = 1) |
| Corticosteroid (topical), PUVA, interferon-α | 1 | 0 (0.0%) | N/A | 1 (100.0%) | NR | 0 (0.0%) | 0 (0.0%) | NR |
| Corticosteroid (topical), retinoid (oral), interferon-α | 1 | 0 (0.0%) | N/A | 0 (0.0%) | N/A | 1 (100.0%) | 0 (0.0%) | NR |
| Corticosteroid (topical), retinoid (oral), PUVA | 1 | 1 (100.0%) | 90.0 (n = 1) | 0 (0.0%) | N/A | 0 (0.0%) | 0 (0.0%) | 48.0 (n = 1) |
| Corticosteroid (topical), retinoid (oral), UVB | 1 | 0 (0.0%) | N/A | 0 (0.0%) | N/A | 1 (100.0%) | 0 (0.0%) | NR |
| Corticosteroid (topical), UVB, interferon-α | 1 | 0 (0.0%) | N/A | 0 (0.0%) | N/A | 1 (100.0%) | 0 (0.0%) | NR |
| Corticosteroid (topical), antihistamine, antifungal | 1 | 0 (0.0%) | N/A | 1 (100.0%) | NR | 0 (0.0%) | 0 (0.0%) | 24.0 (n = 1) |
| Corticosteroid (topical), antihistamine, immunosuppressant∗, PUVA | 1 | 0 (0.0%) | N/A | 1 (100.0%) | NR | 0 (0.0%) | 0 (0.0%) | 10.0 (n = 1) |
| Corticosteroid (topical), antihistamine, immunosuppressant∗, UVB | 1 | 0 (0.0%) | N/A | 1 (100.0%) | NR | 0 (0.0%) | 0 (0.0%) | NR |
| Corticosteroid (oral), PUVA | 5 | 1 (20.0%) | NR | 4 (80.0%) | 28.0 (n = 1) | 0 (0.0%) | 0 (0.0%) | 108.0 (n = 3) |
| Corticosteroid (oral), immunosuppressant∗ | 5 | 1 (20.0%) | 150.0 (n = 1) | 2 (40.0%) | 90.0 (n = 1) | 2 (40.0%) | 0 (0.0%) | 10.0 (n = 4) |
| Corticosteroid (oral), antihistamine | 4 | 0 (0.0%) | N/A | 2 (50.0%) | 30.0 (n = 1) | 2 (50.0%) | 0 (0.0%) | 2.0 (n = 1) |
| Corticosteroid (oral), UVB | 2 | 0 (0.0%) | N/A | 1 (50.0%) | N/A | 1 (50.0%) | 0 (0.0%) | NR |
| Corticosteroid (oral), antihistamine, PUVA | 2 | 0 (0.0%) | N/A | 2 (100.0%) | NR | 0 (0.0%) | 0 (0.0%) | NR |
| Corticosteroid (oral), antihistamine, UVB | 1 | 0 (0.0%) | N/A | 1 (100.0%) | 90.0 (n = 1) | 0 (0.0%) | 0 (0.0%) | NR |
| Corticosteroid (oral), PUVA, interferon-α | 1 | 0 (0.0%) | N/A | 0 (0.0%) | N/A | 1 (100.0%) | 0 (0.0%) | NR |
| Retinoid (oral), PUVA | 5 | 3 (60.0%) | 180.0 (n = 3) | 2 (40.0%) | 28.0 (n = 1) | 0 (0.0%) | 0 (0.0%) | 30.3 (n = 3) |
| Retinoid (oral), UVB | 1 | 0 (0.0%) | N/A | 0 (0.0%) | N/A | 1 (100.0%) | 0 (0.0%) | NR |
| Retinoid (oral), PUVA, interferon-α | 1 | 1 (100.0%) | 365.0 (n = 1) | 0 (0.0%) | N/A | 0 (0.0%) | 0 (0.0%) | 36.0 (n = 1) |
| Retinoid (oral), antibiotic‡, interferon-α | 1 | 0 (0.0%) | N/A | 0 (0.0%) | N/A | 1 (100.0%) | 0 (0.0%) | NR |
| Immunosuppressant, folic acid | 2 | 1 (50.0%) | 90.0 (n = 1) | 1 (50.0%) | 60.0 (n = 1) | 0 (0.0%) | 0 (0.0%) | 19.5 (n = 2) |
| PUVA, antibiotic‡ | 1 | 1 (100.0%) | NR | 0 (0.0%) | N/A | 0 (0.0%) | 0 (0.0%) | NR |
n, number of eruptions, denominator for percentages; %, percentage.
N/A, Not applicable; NR, not reported; PEO, papuloerythroderma of Ofuji; PUVA, psoralen and ultraviolet A; UVB, ultraviolet B.
∗
Cyclosporine.
†
Tacrolimus.
‡
Unreported type.
§
Amoxycillin and clavulanic acid.
‖
Methotrexate.